Related Experiment Video
Updated: Jun 17, 2026
14:14
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Circulating tumour-derived predictive biomarkers in oncology
Darren R Hodgson1, Robert Wellings, Maria C M Orr
1Oncology Therapy Area, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. darren.hodgson@astrazeneca.com
Drug Discovery Today
|January 5, 2010
Summary
Molecular tumor characterization using blood samples is advancing. Analyzing circulating tumor cells and DNA offers a convenient way to guide cancer treatment decisions.
Area of Science:
- Oncology
- Molecular Diagnostics
- Clinical Research
Background:
- Molecular characterization of tumors is crucial for personalized medicine.
- Current methods may be invasive or complex.
- Non-invasive biomarkers are needed for efficient patient selection and treatment.
Purpose of the Study:
- To review the progress in using circulating tumor-derived factors for treatment guidance.
- To highlight the potential of blood-based molecular profiling.
- To discuss the implications for clinical practice and trials.
Main Methods:
- Literature review of recent advances in liquid biopsy.
- Discussion of techniques for analyzing circulating tumor cells (CTCs).
- Exploration of methods for detecting circulating tumor DNA (ctDNA).
Main Results:
- Circulating tumor cells and DNA can reflect tumor molecular characteristics.
- Blood-based analysis offers a minimally invasive approach.
- These biomarkers show promise for guiding treatment selection.
Conclusions:
- Liquid biopsies are emerging as a powerful tool in oncology.
- Molecular profiling from blood samples can streamline patient management.
- Further research will enhance the clinical utility of these circulating biomarkers.
